|Dr. Riad Sherif M.B.A., M.D.||CEO & Director||N/A||N/A||1968|
|Ms. Sylvia Cheung||Chief Financial Officer||N/A||N/A||1975|
|Mr. Weibo Ding||Global COO & GM of China||N/A||N/A||1971|
|Dr. Bastian Dehmel||Chief Development Officer & Head of Development||N/A||N/A||1971|
|Dr. Joanne Chang M.D., Ph.D.||Head of Medical Affairs & Chief Medical Officer||N/A||N/A||1961|
|Mr. Páll Ragnar Jóhannesson||Chief Strategy Officer||N/A||N/A||1981|
|Dr. Fang Li||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Rebecca Weil||Chief Commercial Officer||N/A||N/A||N/A|
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Oculis Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.